P Bertault-Pérès

606 total citations
20 papers, 328 citations indexed

About

P Bertault-Pérès is a scholar working on Pediatrics, Perinatology and Child Health, Oncology and Transplantation. According to data from OpenAlex, P Bertault-Pérès has authored 20 papers receiving a total of 328 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pediatrics, Perinatology and Child Health, 6 papers in Oncology and 6 papers in Transplantation. Recurrent topics in P Bertault-Pérès's work include Renal Transplantation Outcomes and Treatments (6 papers), Drug Transport and Resistance Mechanisms (6 papers) and Antibiotics Pharmacokinetics and Efficacy (5 papers). P Bertault-Pérès is often cited by papers focused on Renal Transplantation Outcomes and Treatments (6 papers), Drug Transport and Resistance Mechanisms (6 papers) and Antibiotics Pharmacokinetics and Efficacy (5 papers). P Bertault-Pérès collaborates with scholars based in France and Japan. P Bertault-Pérès's co-authors include Patrick Maurel, Stéphane Honoré, Pierre Renaudin, Laurent Boyer, Marie‐Anne Estève, Pascal Auquier, Alain Durand, G Fabre, J. P. Cano and J.C. Montet and has published in prestigious journals such as PLoS ONE, Cancer and Transplantation.

In The Last Decade

P Bertault-Pérès

20 papers receiving 323 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P Bertault-Pérès France 10 85 85 81 75 46 20 328
Molouk Hadjibabaie Iran 11 38 0.4× 71 0.8× 22 0.3× 89 1.2× 22 0.5× 32 414
Mary W Roederer United States 13 180 2.1× 102 1.2× 272 3.4× 41 0.5× 12 0.3× 22 458
Tom Lea‐Henry Australia 6 69 0.8× 32 0.4× 27 0.3× 23 0.3× 32 0.7× 12 355
Sireen Abdul Rahim Shilbayeh Saudi Arabia 10 49 0.6× 27 0.3× 24 0.3× 48 0.6× 32 0.7× 51 276
Gunar Stemer Austria 10 50 0.6× 126 1.5× 18 0.2× 19 0.3× 136 3.0× 22 475
Busba Chindavijak Thailand 9 71 0.8× 28 0.3× 63 0.8× 61 0.8× 7 0.2× 27 395
Hans Mulder Netherlands 7 71 0.8× 40 0.5× 133 1.6× 130 1.7× 6 0.1× 8 337
Jill Bates United States 11 43 0.5× 100 1.2× 33 0.4× 75 1.0× 3 0.1× 30 363
Laura Peeters Netherlands 12 22 0.3× 28 0.3× 39 0.5× 12 0.2× 31 0.7× 29 437
Sze Ling Chan Singapore 13 66 0.8× 40 0.5× 127 1.6× 35 0.5× 3 0.1× 58 474

Countries citing papers authored by P Bertault-Pérès

Since Specialization
Citations

This map shows the geographic impact of P Bertault-Pérès's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P Bertault-Pérès with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P Bertault-Pérès more than expected).

Fields of papers citing papers by P Bertault-Pérès

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P Bertault-Pérès. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P Bertault-Pérès. The network helps show where P Bertault-Pérès may publish in the future.

Co-authorship network of co-authors of P Bertault-Pérès

This figure shows the co-authorship network connecting the top 25 collaborators of P Bertault-Pérès. A scholar is included among the top collaborators of P Bertault-Pérès based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P Bertault-Pérès. P Bertault-Pérès is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Boutière, Clémence, Audrey Rico, Frédéric Vely, et al.. (2024). Effect of Prior Treatment With Fingolimod on Early and Late Response to Rituximab/Ocrelizumab in Patients With Multiple Sclerosis. Neurology Neuroimmunology & Neuroinflammation. 11(3). e200231–e200231. 2 indexed citations
2.
Curti, Christophe, et al.. (2023). Low-dose erythromycin in pediatrics: Formulation and stability of 20 mg hard gelatin capsules. PLoS ONE. 18(2). e0282164–e0282164. 5 indexed citations
3.
Primas, Nicolas, et al.. (2022). Pre-formulation and Stability Study of 20-mcg Clonidine Hydrochloride Pediatric Capsules. The Journal of Pediatric Pharmacology and Therapeutics. 27(7). 625–631. 2 indexed citations
4.
Curti, Christophe, et al.. (2021). Beyond-Use Dates Assignment for Pharmaceutical Preparations: Example of Low-Dose Amiodarone Capsules. Journal of Pharmacy Technology. 37(4). 178–185. 5 indexed citations
5.
Perez, Thomas, Audrey Rico, Clémence Boutière, et al.. (2020). Comparison of rituximab originator (MabThera®) to biosimilar (Truxima®) in patients with multiple sclerosis. Multiple Sclerosis Journal. 27(4). 585–592. 14 indexed citations
6.
Renaudin, Pierre, Laurent Boyer, Marie‐Anne Estève, et al.. (2016). Do pharmacist‐led medication reviews in hospitals help reduce hospital readmissions? A systematic review and meta‐analysis. British Journal of Clinical Pharmacology. 82(6). 1660–1673. 91 indexed citations
7.
Rome, Angélique, et al.. (2016). Computerized Provider Order Entry Using Two Prescription-Writing Software in Oncology. American Journal of Medical Quality. 32(2). 220–220. 2 indexed citations
8.
Devictor, B, Bertrand Dussol, É. Lechevallier, et al.. (2003). Comparative study on two kidney graft rinsing and preservation solutions in terms of the post-transplantation risk of delayed graft function and cost. Journal of Clinical Pharmacy and Therapeutics. 28(4). 273–277. 4 indexed citations
9.
Villani, P., et al.. (2001). [Prescriptions and consumption of hypnotic and anxiolytic drugs in the South University Hospital of Marseille].. PubMed. 56(1). 11–4. 9 indexed citations
10.
Queneau, P, et al.. (1997). Effects of tauroursodeoxycholate solutions on cyclosporin A bioavailability in rats.. PubMed. 25(8). 912–6. 15 indexed citations
11.
Astoul, P., et al.. (1994). Pharmacokinetics of intrapleural recombinant interleukin-2 in immunotherapy for malignant pleural effusion. Cancer. 73(2). 308–313. 18 indexed citations
12.
Queneau, P, et al.. (1994). Improvement of cyclosporin A-induced cholestasis by tauroursodeoxycholate in a long-term study in the rat. Digestive Diseases and Sciences. 39(7). 1581–1585. 23 indexed citations
13.
Queneau, P, P Bertault-Pérès, E Mesdjian, Alain Durand, & J.C. Montet. (1993). DIMINUTION OF AN ACUTE CYCLOSPORIN-INDUCED CHOLESTASIS BY TAUROURSODEOXYCHOLATE IN THE RAT. Transplantation. 56(3). 530–534. 17 indexed citations
14.
Bertault-Pérès, P, et al.. (1990). Pharmacokinetics of cyclosporine A in bilateral lung transplantation candidates with cystic fibrosis.. PubMed. 22(4). 1706–7. 6 indexed citations
15.
Vernillet, Laurent, et al.. (1990). French multicentre study: comparison of two specific and four nonspecific methods for Sandimmune (cyclosporine) blood and plasma (separated at 37 degrees C or at 22 degrees C) monitoring.. PubMed. 22(3). 1218–23. 2 indexed citations
16.
Vernillet, Laurent, et al.. (1989). Lack of effect of spiramycin on cyclosporin pharmacokinetics [see comments]. British Journal of Clinical Pharmacology. 27(6). 789–794. 13 indexed citations
17.
Bertault-Pérès, P, et al.. (1989). A novel technique for plasma CsA determination--application to drug monitoring during transplantation.. PubMed. 21(1 Pt 1). 904–5. 1 indexed citations
18.
Fabre, Isabelle, Gabin Fabre, Patrick Maurel, P Bertault-Pérès, & Jean Paul Cano. (1988). Metabolism of cyclosporin A. III. Interaction of the macrolide antibiotic, erythromycin, using rabbit hepatocytes and microsomal fractions.. Drug Metabolism and Disposition. 16(2). 296–301. 31 indexed citations
19.
Bertault-Pérès, P, Claude Bonfils, G Fabre, et al.. (1987). Metabolism of cyclosporin A. II. Implication of the macrolide antibiotic inducible cytochrome P-450 3c from rabbit liver microsomes.. Drug Metabolism and Disposition. 15(3). 391–398. 56 indexed citations
20.
Fabre, G, et al.. (1987). Metabolism of cyclosporin A. I. Study in freshly isolated rabbit hepatocytes.. Drug Metabolism and Disposition. 15(3). 384–390. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Molouk Hadjibabaie Breakdown of academic impact, for papers by Mary W Roederer Breakdown of academic impact, for papers by Tom Lea‐Henry Breakdown of academic impact, for papers by Sireen Abdul Rahim Shilbayeh Breakdown of academic impact, for papers by Gunar Stemer Breakdown of academic impact, for papers by Busba Chindavijak Breakdown of academic impact, for papers by Hans Mulder Breakdown of academic impact, for papers by Jill Bates Breakdown of academic impact, for papers by Laura Peeters Breakdown of academic impact, for papers by Sze Ling Chan
Rankless by CCL
2026